TNF-α, IL-6 and their soluble receptor serum levels and secretion by neutrophils in cancer patients

Archivum Immunologiae et Therapiae Experimentalis

Volumn 49, Issue 1, 2001, Pages 63-69

  Jabłońska, Ewa ^b   Kiluk, Marek ^a   Markiewicz, Włodzimierz ^a   Piotrowski, Leszek ^c   Grabowska, Zyta ^c   Jabłoński, Jakub ^c  

^a Regional Centre of Oncology   (Poland)

^b MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^c NONE

Author keywords

Breast cancer; Interleukin 6; Oral cavity cancer; Soluble IL 6 receptor; Soluble TNF receptor; Tumor necrosis factor

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; LEUKOCYTE ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BLOOD; BREAST TUMOR; CASE CONTROL STUDY; FEMALE; HUMAN; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; MOUTH TUMOR; NEOPLASM; NEUTROPHIL; SECRETION; SOLUBILITY; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; ANTIGENS, CD; BREAST NEOPLASMS; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASMS; NEUTROPHILS; RECEPTORS, INTERLEUKIN-6; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SOLUBILITY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035220443     PISSN: 0004069X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. ABBATE I., CORREALE M. and GARGANO G. (1992): Tumor necrosis factor and soluble interleukin-2 two immunological biomarkers in female neoplasms. Eur. J. Gynecol. Oncol., 13, 92-96.
2. ADERKA D., LE J. and VILCEK J. (1989): IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937, and in mice. J. Immunol., 143, 3517-3523.
3. BEMELMANS M. H. A., GOUMA D. J. and BUURMAN W. A. (1993): LPS-induced sTNF-receptor release in vivo in a murine model. J. Immunol., 151, 5554-5562.
4. DENZ H., ORTH B., WEISS G., GALLATTI H., HERRMAN R., HUBER P., WATCHER H. and FUCHS D. (1993): Serum soluble tumor necrosis factor receptor p55 is increased in patients with haematological neoplasias and is associated with immune activation and weight loss. Eur. J. Cancer, 29, 2232-2235.
5. DORE P., LELIEVRE E., MOREL F., BRIZARD A., FORCIN M., CLEMENT C., INGRAND P., DANESKI L., GASCAN H., WIJDENES J., GOMBERT J., PREU'DHOME J. L. and LECRON J. C. (1997): IL-6 and soluble IL-6 receptors (sIL-6R and sgp130) in human pleural effusions: massive IL-6 production independently of underlying diseases. Clin. Exp. Immunol., 107, 182-188.
6. ELSASSER-BEILE U. and VON KLEIST S. (1993): Cytokines as therapeutic and diagnostic agents. Tumor Biol., 14, 69-94.
7. FILELLA X., BLADE J., LOPEZ G. A., MOLINA R., ROZMAN C. and BALLESTA A. M. (1996): Cytokines (IL-6, TNF-α, IL-1α) and soluble interleukin-2 receptor as serum tumor markers in multiple myeloma. Cancer Detect. Prev., 20, 52-56.
8. GALLO O., GORI A. and ATTANASIO M. (1993): Interleukin-1 beta and IL-6 release by peripheral blood monocytes in head and neck cancer. Br. J. Cancer, 68, 465-468.
9. HEANEY M. L and GOLDE D. W. (1998): Soluble receptors in human disease. J. Leukoc. Biol., 64, 135-146.
10. HELLER R. and KRONKE M. J. (1994): Tumor necrosis factor receptor-mediated signalling pathways. Cell. Biol., 126, 5-8.
11. JABLONSKA E. (1998): Changes in sIL-6R and sTNFRs release by PMNs and the serum levels in breast cancer patients at different stages of treatment. Cytokine, 10, 540-543.
12. JABLONSKA E. (1999): Soluble IL-6 and TNF receptors release by polymorphonuclear and mononuclear cells in cancer patients. Neoplasma, 46, 35-19.
13. JABLONSKA E., KILUK M., PIOTROWSKI L., GRABOWSKA Z., MARKIEWICZ W. and JABLONSKI J. (1998): Tumor necrosis factor-alpha and soluble tumor necrosis factor receptors in the culture supernatants of polymorphonuclear cells and peripheral blood mononuclear cells from cancer patients. Eur. Cytokine Netw., 9, 155-159.
14. JOYCE D. A. and STEER J. H. (1996): IL-4, IL-10 and IFN-gamma have distinct, but interacting, effects on differentiation-induced changes in TNF-alpha and TNF receptor release by cultured human monocytes. Cytokine, 8, 49-58.
15. KISHIMOTO T., AKIRA S., NARAZAKI M. and TAGA T (1995): Interleukin-6 family of cytokines and gp130. Blood, 86, 1243-1254.
16. MANTOVANI A., BUSSOLINO F. and DEJANA F. (1992): Cytokine regulation of endothelial cell function. FASEB J., 6, 2591-2598.
17. MCGEE D. W., BAMBERG T., VITKUS J. D. and MCGEE J. R. (1995): A synergistic relationship between TNF-α, IL-1β and TGF-β on IL-6 secretion by IEC-6 intestinal epithelial cell line. Immunology, 86, 6-11.
18. NAKAZAKI H. (1992): Preoperative and postoperative cytokines in patients with cancer. Cancer 3, 709-716.
19. PORTEU F., BROCHAUS M., WALLACH D., ENGELMAN H. and NATHAN C. F. (1991): Human neutrophils elastase releases a ligand-binding fragment from 75-kDa tumor necrosis factor (TNF) receptor. J. Biol. Chem., 266, 18846-18853.
20. REID S. E., SCANLON E. F., KAUFMAN M. W. and MURTHY M. S. (1996): Role of cytokines and growth factors in promoting the local recurence of breast cancer. Br. J. Surg., 83, 313-320.
21. REZZONICO R., PONZIO G., LOUBAT A., ROCHET N., FAR D. F. and Rossi B. (1997): Interleukin-6 stimulates a tyrosine kinase activity potentially involved in mouse hybridorna cell growth. Cytokine, 9, 93-100.
22. SCHULER M., PESCHEL C., SCHNELLER F., FICHTNER J., FABER L., HUBER C. and AULITZKY W. E. (1996): Immunomodulatory and hematopoietic effects of recombinant human interleukin-6 in patients with advanced renal cell cancer. J. Interferon Cytokine Res., 16, 903-910.
23. UOTILA P. (1996): The role of cyclic AMP and oxygen intermediates in the inhibition of cellular immunity in cancer. Cancer Immunol. Immunother., 43, 1-9.
24. ZEMAN K., TCHÓRZEWSKI H., MAJEWSKA E., POKOCA L. and PINKOWSKI R. (1988): A simple method for simultaneous purification of peripheral blood lymphocytes and granulocytes. Pol. J. Immunol., 13, 225-232.